

Humber Area Prescribing Committee

Date / Time	1 st May 2024 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	Yes

Attendance	Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Luke Storr – Senior Pharmacy Technician, HUTH (LS) Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK) Simon Priestley- Chief Pharmacist, NLAG (SP) Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Daniel Newsome- Principal Pharmacist RDTC (DN) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Joanne Goode – Chief Pharmacist – HUTH (JG) Dr Rolan Schreiber, Medical Secretary LMC (RSc) Laura Angus- Chief Pharmacy Officer/ Director of Pharmacy and Medicines Optimisation- NHS Humber and North Yorkshire ICB (LA) Natasha Suffill- Lead Clinical Pharmacist CHCP (NS) Prof A Morice, Professor of Respiratory Medicine HUTH- (AM) Catherine Smith- Senior Medicines Optimisation Pharmacist, NECS Narayana Pothina- Consultant in adult medicine, NLAG (NP) Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK) Dr Pratik Basu- GP- The Birches medical practice (PB) Weeliat Chong, Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC)
-------------------	---

Apologies

Agenda Number	Item	Discussion	Action	Lead	Due Date
2024.05.01	Apologies	Noted above			
2024.05.02	Declarations of interest	None			
2024.05.03	Minutes of previous meeting	Accepted as true record			
2024.05.04	Action Tracker	<p>Outstanding actions from NLAPC</p> <p>Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs)</p> <p>JM to provide RS information on number of patients in NEL/NL</p> <p>December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole</p> <p>February update: RS confirmed SCFs for modafinil and riluzole available within NEL; JM to upload SCFs (riluzole and modafinil for NEL).</p> <p>March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update</p> <p>April update: Riluzole to JM to update websites to include NL</p> <p>May update: Riluzole updated, modafinil still waiting for NL, mycophenolate to review</p> <p>June update: Modafanil still waiting on NL, JM to review mycophenolate for July guideline group</p> <p>July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group</p> <p>August update: JM corrected typos, changed over on web and sent to RS, JM still to review mycophenolate SCF for September guideline group</p> <p>September 2023 update: For September guideline group</p> <p>October 2023 update: For November Guideline group</p> <p>November 2023 update: For November Guideline group</p> <p>December 2023 update: For January or March guideline group – to check against York mycophenolate.</p>	Ongoing	JM	7/24

	<p>February 2024 update: reviewed against York SCF and contacted neuromuscular lead with national SCF. For March guideline group</p> <p>April 2024 update: RDTC have published reviewed and updated SCF. Neuromuscular lead happy with to update but to do as immunosuppression SCF for all places and specialities that use.</p> <p>May 2024 update: SCF update ongoing</p> <p>Outstanding actions from HERPC</p> <p>Renal repatriation:</p> <p>November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To update further next time.</p> <p>December update – Not met with renal yet.</p> <p>March update – Updating business case.</p> <p>May update – to meet with NHSE</p> <p>August update – not yet met with NHSE</p> <p>September update: not yet met with NHSE</p> <p>October update: not yet met with NHSE</p> <p>November update: not yet met with NHSE</p> <p>December update: meeting arranged with NHSE</p> <p>February update: meeting arranged and business case in progress</p> <p>April 2024 update: JM and LA met with Paul McManus to discuss further.</p> <p>May 2024 update: business case ongoing</p> <p>Blueteq</p> <p>Non-compliance to NICE guidance in acute trusts and financial impact</p> <p>June update: JM to submit ustekinumab report in gastroenterology HUTH when approved</p> <p>JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved</p> <p>July update: JM to update next time.</p> <p>August update: no further update, infliximab audit in HUTH started</p> <p>September update: HUTH audits still ongoing</p> <p>October update: HUTH audits still ongoing</p> <p>November update: HUTH audits still ongoing</p> <p>December 2023 update: HUTH audits still ongoing, infliximab need more data and started adalimumab audit for homecare patients as recently done brand/provider switch.</p>	Ongoing	JM	10/24
	<p>May 2024 update: business case ongoing</p> <p>Blueteq</p> <p>Non-compliance to NICE guidance in acute trusts and financial impact</p> <p>June update: JM to submit ustekinumab report in gastroenterology HUTH when approved</p> <p>JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved</p> <p>July update: JM to update next time.</p> <p>August update: no further update, infliximab audit in HUTH started</p> <p>September update: HUTH audits still ongoing</p> <p>October update: HUTH audits still ongoing</p> <p>November update: HUTH audits still ongoing</p> <p>December 2023 update: HUTH audits still ongoing, infliximab need more data and started adalimumab audit for homecare patients as recently done brand/provider switch.</p>	Ongoing	JM	6/24

		<p>February 2024 update: Ustekinumab audit outcome form presented which demonstrated compliance with NICE guidance.</p> <p>March 2024 update: Infliximab paper due to presented at April D&TC</p> <p>April 2024 update: HUTH D&TC not until next week to update next time</p> <p>May 2024 update: Infliximab paper presented to HUTH D&TC at last meeting alongside updated guidance (on agenda). HUTH infliximab IBD audit was presented to D&TC and noted multiple dosage regimens are in use. Evaluated cost effectiveness versus current second line agents (vedolizumab or ustekinumab) and escalated infliximab is significantly more cost effective. This will be reviewed as more biosimilar agents become available.</p> <p>Outstanding actions from HERPC: Rheumatology to prepare pathway with rituximab without MTX</p> <p>August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&TC action tracker. To discuss at September D&TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway, to enable JM to start writing paper.</p> <p>September update: September D&TC next week, further updates to pathway needed</p> <p>October update: Awaiting updated pathway</p> <p>November update: Pathway needs further updates as new TAs published again and pharmacist who is updating has prioritised adalimumab switch.</p> <p>December update: ongoing</p> <p>February 2024 update: JG to follow up with Dr Ogumbambi</p> <p>March 2024 update: JG raised at HUTH D&TC; to bring NLAG RA pathway to next guideline group and invite Dr Alvi.</p> <p>April 2024 update: NLAG RA pathway on agenda</p> <p>May 2024 update: HUTH RA pathway currently circulating rheumatologists for comment.</p> <p>Ratification of guidelines and SCFs: Sick Day Guidance in T2DM</p> <p>JM to discuss with Matthew Heppel about printing this in colour/black and white and discuss with comms team</p> <p>December 2023 – ongoing</p>	Ongoing	JM	6/24
			Ongoing	JM	6/24

		<p>February 2024 – ongoing April 2024 – ongoing May 2024 – reviewed wording of document to simplify and transferred into black and white. To add to agenda next month Ratification of guidelines and SCFs: Amiodarone SCF JM to do minor updates and feedback to cardiology team at HUTH; check patient number for NEL/NL from NLAG/HUTH September 2023 update: JM fed back to cardiology team and updated. JM/AK to confirm patient numbers being dispensed at NLAG sites. October 2023 – RS fed back comments from NEL/NL GP leads. JM sent comments to cardiology team. JM confirmed patient numbers from outsourced outpatients at NLAG. November 2023 – to be discussed at next cardiology governance December 2023 - received comments from cardiology JM to review and send to RS/Catherine Smith after review February 2024 update: ongoing March 2024 update: JM to send updated SCF to CS for review. April 2024 update: ongoing May 2024: reviewed and needs reviewing against RDTC documentation. Either back to guideline/SCF group or to APC dependant on number of changes.</p> <p>Feedback from Integrated Medicines Optimisation Committee - Sodium valproate prevent compliance December 2023 –RS sent JM audit report and JM fed back to neurologists who state all their patients have annual review and forms. March 2024 update – ICB meetings with stakeholders underway. JM updating HUTH internal policy which will be shared with NLAG. April 2024 update – ICB meetings ongoing. JM meeting with HUTH team to look at internal improvements. May 2024 update – work in HUTH ongoing</p> <p>Work plans To add RDTC SCF to guideline/SCF group to review against local SCFs when published April 2024 update – work ongoing to review SCF workplan. May 2024 update – work ongoing</p> <p>Ratification of guidelines and SCFs</p>	Ongoing	JM	7/24
		<p>Feedback from Integrated Medicines Optimisation Committee - Sodium valproate prevent compliance December 2023 –RS sent JM audit report and JM fed back to neurologists who state all their patients have annual review and forms. March 2024 update – ICB meetings with stakeholders underway. JM updating HUTH internal policy which will be shared with NLAG. April 2024 update – ICB meetings ongoing. JM meeting with HUTH team to look at internal improvements. May 2024 update – work in HUTH ongoing</p> <p>Work plans To add RDTC SCF to guideline/SCF group to review against local SCFs when published April 2024 update – work ongoing to review SCF workplan. May 2024 update – work ongoing</p> <p>Ratification of guidelines and SCFs</p>	Ongoing	JM/KMc	8/24
		<p>Work plans To add RDTC SCF to guideline/SCF group to review against local SCFs when published April 2024 update – work ongoing to review SCF workplan. May 2024 update – work ongoing</p> <p>Ratification of guidelines and SCFs</p>	Ongoing	LS/JM	6/24
		<p>Ratification of guidelines and SCFs</p>	Ongoing	JM	4/24

		<p>To add information around initial supply of devices to erectile dysfunction following prostatectomy guidance April 2024 update: ongoing May 2024: ongoing</p> <p>Ratification of guidelines and SCFs To upload erectile dysfunction following prostatectomy to website and update formulary when uploaded April 2024 update: ongoing May 2024 update: ongoing</p> <p>RTDC updates To contact local services to discuss update of pathways and providing feedback to APC in timely manner. JM – to contact joint dermatology services hosted by HUTH (TA916), HUTH rheumatology (TA916/TA918/TA920), joint neurology services hosted by HUTH (TA919) and HUTH gastroenterology (TA925) JM to provide OA with HUTH IBD pathway to discuss with clinical lead. OA to contact NLAG gastroenterology(TA925) with HUTH pathway and NLAG rheumatology (TA916/TA918/TA920) March 2024 update: JM contacted dermatology, rheumatology and awaiting updated guidance, JM contacted neurology and updated guidance on agenda, JM contacted gastroenterology and TA925 already within APC approved pathway. OA contacted NLAG gastroenterology with HUTH guidance agreed to review guidance and aim for next version to be joint guidance. OA contacted NLAG rheumatology April 2024 update: ongoing with with gastro to look at merging guidance. JM met with Prof. Sebastian (IBD lead at HUTH) who is happy to liaise with NLAG as they develop their IBD service.</p>	Ongoing	JM	4/24
			Ongoing	JM	2/24
2024.05.05	Traffic Light Status	<p>Arikayce- Proposed as RED Hylo-Dual Intense- Proposed as AMBER 1 (specialist initiation only) Adex- Not approved for info only Targeted release budesonide- Proposed as RED Etrasimod- Proposed as RED Nicorette (quick mist)- Proposed as PURPLE Duraphat toothpaste- Proposed as PURPLE/AMBER 1</p> <p>CGM Sensors – FSL2+ and Dexcom1+ recommended to IPMOC for approval (option 2 – approve onto formulary with</p>	To update formulary	JM/LS/AK	6/24

		new patients to be prescribed FSL2+ and Dexcom 1+ and transition existing patients as and when necessary.			
2024.05.06	Feedback from Integrated Medicines Optimisation Committee	<ul style="list-style-type: none"> Further conversations around one system formulary. Laura Angus currently writing a plan and options paper around this. Nil else for APC. 	Noted		
2024.05.07	Work plans	<ol style="list-style-type: none"> Joint formulary alignment Shared care frameworks Guidelines 	Ongoing for information only		
2024.05.08	Ratification of joint formulary	<ul style="list-style-type: none"> Chapter 3 Chapter 11 	Approved Approved		
2024.05.09	Ratification of guidelines and SCFs	<ol style="list-style-type: none"> Ocular Lubricant – this guidance is based on the HERPC guidance and has been reviewed by ophthalmology. IBD Guideline including Pathway (HUTH) – updated pathway including new TA (etrasimod), additional tables and changes around infliximab dosing escalations which have been approved via HUTH D&Tc. 	<ol style="list-style-type: none"> approved approved 	JM	6/24
2024.05.10	RDTC updates	<ul style="list-style-type: none"> March 2024 	Update formulary/red list	JM/LS/AK	7/24
2024.05.11	Minutes from subcommittees	<ol style="list-style-type: none"> Joint formulary subcommittee (Feb 24) Guideline subcommittee (Nil) 	Attached for info only		
2024.05.12	Additional minutes for information	<ol style="list-style-type: none"> HUTH D&TC (Nil) HFT DTG (Nil) NLAG M&T (Nil) NYA APC (Nil) 	Attached for info only		
2024.05.13	Correspondence received	Nil this month			
2024.05.14	AOB	<ul style="list-style-type: none"> Signatures for shared care and updating template to reflect national position on who can sign SCFs. JM to update template for next meeting (to go to guideline group inbetween). 	Update template	JM	6/24
2024.05.15	Date of next meeting	5 th June 2024 13.00 – 15.00 Teams			